MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report released on Monday. The brokerage set a “buy” rating on the stock.

Separately, Stifel Nicolaus restated a “hold” rating and set a $7.00 price objective on shares of MEI Pharma in a research report on Friday, April 12th.

MEI Pharma Price Performance

Shares of MEI Pharma stock opened at $2.86 on Monday. The company’s fifty day simple moving average is $3.03 and its 200-day simple moving average is $4.13. The stock has a market capitalization of $19.06 million, a PE ratio of 0.73 and a beta of 0.80. MEI Pharma has a 1-year low of $2.73 and a 1-year high of $7.87.

MEI Pharma (NASDAQ:MEIP) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.01. MEI Pharma had a net margin of 39.06% and a return on equity of 48.32%. As a group, research analysts anticipate that MEI Pharma will post 3.22 EPS for the current year.

Institutional Trading of MEI Pharma

A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI bought a new position in MEI Pharma, Inc. (NASDAQ:MEIP) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent SEC filing. 52.38% of the stock is owned by institutional investors and hedge funds.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.